Huang, Jiawei
Deng, Qingwen
Tsang, Lai Ling
Chang, Guozhu
Guo, Jinghui
Ruan, Ye Chun
Wang, Chi Chiu
Li, Gang
Chan, Hon Fai
Zhang, Xiaohu
Jiang, Xiaohua https://orcid.org/0000-0002-7372-4961
Funding for this research was provided by:
Innovation and Technology Commission - Hong Kong (MHP/024/19, ITS/448/18)
National Key Research and Development Program of China (2019 YFE0198400)
Sichuan Science and Technology Program (2023ZYD0118, 2023NSFSC0530, 2020 YFH0041)
Guangdong Province Basic and Applied Basic Research Fund (2024A1515012929)
Science and Technology Planning Project of Guangdong Province of China (2023B1212120009)
Article History
Received: 12 August 2024
Accepted: 13 January 2025
First Online: 8 February 2025
Declarations
:
: Isolation of human umbilical cord- and placenta-derived MSCs was approved by the Joint CUHK-NTEC Clinical Research Ethics Committee (Title: Placenta derived genes analysis in placenta and maternal circulation in singleton pregnancies complicated with fetal growth restriction; Ref: 2020.313; Year of approval: 2020). The use of human bone marrow for MSC isolation was approved by Joint CUHK-NTEC Clinical Research Ethics Committee (Title: A novel preclinical treatment strategy for enhancing chemosensitivity of pediatric B-precursor acute lymphoblastic leukemia by disruption of leukemia-stroma interaction using CD9-neutralizing antibody in a mouse model; Ref: 2015.018; Year of approval: 2015). Written informed consent for participation in the study or the use of samples was provided to the patients or their guardians. All animal use and research protocols in this study were approved by the Laboratory Animal Experimentation Ethical Committee, Chinese University of Hong Kong (Title: Development of stem cell-based therapy for diabetic foot ulcer (DFU); Ref: 21–162-MIS; Year of approval: 2021) and were in accordance with the Guideline for the Care and Use of Laboratory Animals.
: Not applicable.
: The authors declare that they have no competing interests.